View Risk


Article data
Mancia (2020)
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
10.1056/NEJMoa2006923
https://pubmed.ncbi.nlm.nih.gov/32356627/

Results
Treatment
Treatment history (Treated with calcium channel blocker vs. Not received)
COVID-19 (any condition)
Odds ratio: 1.030 (0.950-1.120) Adjusted model

Study characteristics

Italy

Case-control study

Medical records

37301

6272 case patients in whom infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed between February 21 and March 11, 2020, were matched to 30,759 beneficiaries of the Regional Health Service (controls) according to sex, age, and municipality of residence.

Age cases yr 68±13 ; Female sex — no. (%) 2303 (36.7)

0


Results

COVID-19 (any condition)

6272

Diagnosis was based on the protocol released by the World Health Organization — that is, positive nasopharyngeal swab specimens tested with at least two real-time reverse-transcriptase–polymerase-chain-reaction assays targeting different genes (E, RdRp, and M) of SARSCov-2. patients with a diagnosis of Covid-19

Treatment

Treatment history

Treated with Calcium channel blocker in the last year (2019)

Not received

Treated with calcium channel blocker

Odds ratio

1.030 (0.950-1.120)

No

No

Yes

Estimates were fully adjusted for drug therapies and comorbidities


Other information

none

Average

No

Go Back